Journal of Clinical Densitometry
Volume 12, Issue 1 , Pages 1-4 , January 2009

Identification of Factors Influencing the Intervention Thresholds for Treatment of Osteoporosis Based on 10-Year Absolute Fracture Risks

References 

  1. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989–995
  2. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581–589
  3. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2005;56:178–188
  4. Tucker G, Metcalfe A, Pearce C, et al. The importance of calculating absolute rather than relative fracture risk. Bone. 2007;41:937–941
  5. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129
  6. Brown JP, Josse RG. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:S1–S34
  7. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000;11:192–202
  8. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary. Osteoporos Int. 1998;(8 Suppl 4):S3–S6
  9. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:293–312
  10. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795
  11. De Laet C, Oden A, Johansson H, et al. The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int. 2005;16:313–318
  12. Melton LJ. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int. 2001;69:179–181
  13. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889–1897
  14. Leslie WD, Metge C, Ward L. Contribution of clinical risk factors to bone density-based absolute fracture risk assessment in postmenopausal women. Osteoporos Int. 2003;14:334–338
  15. Melton LJ, Johnell O, Lau E, et al. Osteoporosis and the global competition for health care resources. J Bone Miner Res. 2004;19:1055–1058
  16. Leslie WD, Siminoski K, Brown JP. Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women. J Clin Densitom. 2007;10:124–131
  17. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259
  18. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–1244
  19. Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. J Bone Miner Res. 2007;22:781–788
  20. Abrahamsen B, Vestergaard P, Rud B, et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2006;21:796–800
  21. Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int. 2007;18:1109–1117
  22. Kanis JA. On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. University of Sheffield, UK, World Health Organization Collaborating Center for Metabolic Bone Disease, 2007.
  23. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–397
  24. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX((R))-assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395–1408
  25. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51
  26. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  27. Schwartz AV, Kelsey JL, Maggi S, et al. International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Osteoporos Int. 1999;9:242–253
  28. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194
  29. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005;
  30. National Institute for Health and Clinical Excellence . Final Appraisal Determination: Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. London: NICE; 2007;
  31. Kanis JA, Adams J, Borgstrom F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42:4–15
  32. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;
  33. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046

PII: S1094-6950(08)00449-6

doi: 10.1016/j.jocd.2008.10.001

Journal of Clinical Densitometry
Volume 12, Issue 1 , Pages 1-4 , January 2009

Article Tools